Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 8, Issue 3, 2014, Pages 223-233

  Hagihara, Yoshie ^a   Ohfuji, Satoko ^a   Watanabe, Kenji ^a   Yamagami, Hirokazu ^a   Fukushima, Wakaba ^a   Maeda, Kazuhiro ^b   Kamata, Noriko ^a   Sogawa, Mitsue ^a   Shiba, Masatsugu ^a   Tanigawa, Tetsuya ^a   Tominaga, Kazunari ^a   Watanabe, Toshio ^a   Fujiwara, Yasuhiro ^a   Hirota, Yoshio ^a   Arakawa, Tetsuo ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b The Research Foundation for Microbial Diseases of Osaka University   (Japan)

Author keywords

Immune responses; Immunomodulator; Inflammatory bowel disease; Infliximab; Influenza vaccine

Indexed keywords

IMMUNE RESPONSES; IMMUNOMODULATOR; INFLAMMATORY BOWEL DISEASE; INFLIXIMAB; INFLUENZA VACCINE;

6-MERCAPTOPURINE; ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNITY, ACTIVE; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; TACROLIMUS;

EID: 84894031728     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.08.008     Document Type: Article

References (46)

1. Abraham C., Cho J.H. Functional consequences of NOD2(CARD15) mutations. Inflamm Bowel Dis 2006, 12(7):641-650.
2. Aberra F.N., Lichtenstein G.R. Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis 2005, 11(7):685-695.
3. Lichtenstein G.R., Feagan B.G., Cohen R.D., Salzberg B.A., Diamond R.H., Chen D.M., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4(5):621-630.
4. Viget N., Vernier-Massouille G., Salmon-Ceron D., Yazdanpanah Y., Colombel J.F. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008, 57(4):549-558.
5. Toruner M., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Orenstein R., Sandborn W.J., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134(4):929-936.
6. Leung V.S., Nguyen M.T., Bush T.M. Disseminated primary varicella after initiation of infliximab for Crohn's disease. Am J Gastroenterol 2004, 99(12):2503-2504.
7. Deutsch D.E., Olson A.D., Kraker S., Dickinson C.J. Overwhelming varicella pneumonia in a patient with Crohn's disease treated with 6-mercaptopurine. J Pediatr Gastroenterol Nutr 1995, 20(3):351-353.
8. Esteve M., Saro C., González-Huix F., Suarez F., Forné M., Viver J.M. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004, 53(9):1363-1365.
9. Wasan S.K., Baker S.E., Skolnik P.R., Farraye F.A. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 2010, 105(6):1231-1238.
10. Melmed G.Y. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis 2009, 15(9):1410-1416.
11. Schanzer D.L., Langley J.M., Tam T.W.S. Role of influenza and other respiratory viruses in admissions of adults to Canadian hospitals. Influenza Other Respi Viruses 2008, 2(1):1-8.
12. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289(2):179-186.
13. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292(11):1333-1340.
14. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., et al. Emergence of a novel swine-origin influenza A(H1N1) virus in humans. N Engl J Med 2009, 360(25):2605-2615.
15. Jain S., Kamimoto L., Bramley A.M., Schmitz A.M., Benoit S.R., Louie J., et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009, 361(20):1935-1944.
16. deBruyn J.C., Hilsden R., Fonseca K., Russell M.L., Kaplan G.G., Vanderkooi O., et al. Immunogenicity and safety of influenza vaccination in children with bowel disease. Inflamm Bowel Dis 2012, 18(1):25-33.
17. Cullen G., Bader C., Korzenik J.R., Sands B.E. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut 2012, 61(3):385-391.
18. Andrisani G., Frasca D., Romero M., Armuzzi A., Felice C., Marzo M., et al. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants. J Crohns Colitis 2013, 7(4):301-307.
19. Kyriakos N., Papamichael K., Archavlis E., Agalos G., Mantzaris G.J. Long term safety and efficacy of H1N1 vaccine in a single-center cohort of IBD patients treated with immunomodulators and/or anti-TNFα biologics. J Crohns Colitis 2012, 6(2):264-265.
20. Rahier J.F., Papay P., Salleron J., Sebastian S., Marzo M., Peyrin-Biroulet L., et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 2011, 60(4):456-462.
21. Fields S.W., Baiocco P.J., Korelitz B.I. Influenza vaccinations: should they really be encouraged for IBD patients being treated with immunosuppressives?. Inflamm Bowel Dis 2009, 15(5):649-651.
22. Mamula P., Markowitz J.E., Piccoli D.A., Klimov A., Cohen L., Baldassano R.N. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5(7):851-856.
23. Naganuma M., Fujii T., Kunisaki R., Yoshimura N., Takazoe M., Takeuchi Y., et al. Incidence and characteristics of the 2009 influenza (H1N1) infections in inflammatory bowel disease patients. J Crohns Colitis 2013, 7(4):308-313.
24. Lu Y., Jacobson D.L., Ashworth L.A., Grand R.J., Meyer A.L., McNeal M.M., et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009, 104(2):444-453.
25. European Committee for Proprietary Medical Products. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96) 1997, European Agency for the Evaluation of Medical Products, London.
26. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989, 298(6666):82-86.
27. Best W.R., Becktel J.M., Singleton J.W., Kern F. Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology 1976, 70(3):439-444.
28. Best W.R., Becktel J.M., Singleton J.W. Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI). Gastroenterology 1979, 77(4 Pt 2):843-846.
29. Ohfuji S., Fukushima W., Deguchi M., Kawabata K., Yoshida H., Hatayama H., et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine among pregnant women: lowered antibody response by prior seasonal vaccination. J Infect Dis 2011, 203(9):1301-1308.
30. Hirst G.K. The quantitative determination of influenza virus and antibodies by means of red cell agglutination. J Exp Med 1942, 75(1):49-64.
31. Committee for proprietary medicinal products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines 1997, 1-18. The European Agency for the Evaluation of Medicinal Products, London, [EMEA/CPMP/BWP/214/96].
32. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362(15):1383-1395.
33. Melmed G.Y., Ippoliti A.F., Papadakis K.A., Tran T.T., Birt J.L., Lee S.K., et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006, 101(8):1834-1840.
34. Wasan S.K., Coukos J.A., Farraye F.A. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologist's knowledge. Inflamm Bowel Dis 2011, 17(12):2536-2540.
35. Sands B.E., Cuffari C., Katz J., Kugathasan S., Onken J., Vitek C., et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004, 10(5):677-692.
36. Narula N., Dhillon A.S., Chauhan U., Marshall J.K. An audit of influenza vaccination status in adults with inflammatory bowel disease. Can J Gastroenterol 2012, 26(9):593-596.
37. Kunisaki K.M., Janoff E.N. Influenza in immunosuppressed populations: A review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9(8):493-504.
38. Dotan I., Werner L., Vigodman S., Agarwal S., Pfeffer J., Horowitz N., et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis 2012, 18(2):261-268.
39. França I.L., Ribeiro A.C., Aikawa N.E., Saad C.G., Moraes J.C., Goldstein-Schainberg C., et al. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology (Oxford) 2012, 51(11):2091-2098.
40. Romanowska M., Banaszkiewicz A., Nowak I., Radzikowski A., Brydak L.B. Immunization against influenza during the 2005/2006 epidemic season and the humoral response in children with diagnosed inflammatory bowel disease (IBD). Med Sci Monit 2010, 16(9):CR433-CR439.
41. Kobie J.J., Zheng B., Bryk P., Barnes M., Ritchlin C.T., Tabechian D.A., et al. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther 2011, 13(6):R209.
42. Fiorino G., Peyrin-Biroulet L., Naccarato P., Szabò H., Sociale O.R., Vetrano S., et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2012, 18(6):1042-1047.
43. Moses J., Alkhouri N., Shannon A., Raig K., Lopez R., Danziger-lsakov L., et al. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol 2012, 107(1):133-138.
44. Ribeiro A.C., Guedes L.K., Moraes J.C., Saad C.G., Aikawa N.E., Calich A.L., et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis 2011, 70(12):2144-2147.
45. Saad C.G., Borba E.F., Aikawa N.E., Silva C.A., Pereira R.M., Calich A.L., Timenetsky M.D.O.C., Precioso A.R., Bonfa E., et al. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 2011, 70(6):1068-1073.
46. Esteve Comas M., Loras Alastruey C., Fernandez-Bañares F. How do we manage vaccinations in patients with inflammatory bowel disease?. Dig Dis 2009, 27(3):370-374.